CD274 and lung cancer: We then evaluated its performance on an independent dataset of 150 patients with non–small-cell lung cancer (74 patients treated with anti-PD-L1 and 76 treated with anti-PD-L1 + anti-CTLA-4 from the MYSTIC trial [NCT02453282]; Supplementary Note 2).